Literature DB >> 2493675

Vaccinia-interleukin 2 recombinant virus or exogenous interleukin 2 does not alter the magnitude or immune response gene defects of the cytotoxic T-cell response to vaccinia virus in vivo.

A Müllbacher1, I A Ramshaw, B E Coupar.   

Abstract

We investigated the role of interleukin 2 (IL-2), a T cell-derived lymphokine, in the generation of in vivo cytotoxic T-cell responses to vaccinia virus. We made use of a recombinant vaccinia virus encoding and expressing the murine IL-2 gene and recombinant IL-2 to test the role of IL-2 in the expression of major histocompatibility complex (MHC) class I determined immune response (Ir) gene defects in the response to vaccinia virus. IL-2 expressed either by the vaccinia virus vector or exogenous IL-2 does not alter Ir gene defects nor does IL-2 under such conditions elevate the cytotoxic T-cell response in general.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493675     DOI: 10.1111/j.1365-3083.1989.tb01092.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus.

Authors:  D W Ju; X Cao; B Acres
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Authors:  V Bronte; K Tsung; J B Rao; P W Chen; M Wang; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.